Palobiofarma Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Private

  • Employees
  • 20

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $7.71M

  • Investors
  • 13

Palobiofarma General Information

Description

Developer of adenosine receptor modulators designed to advance treatments for orphan and neurological diseases. The company offers virtual drug design, medicinal chemistry, in-vitro pharmacology expertise, and compound characterization capabilities, enabling biopharma researchers and healthcare providers to access targeted therapeutics with improved clinical potential.

Contact Information

Website
www.palobiofarma.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Avenida Ernest Lluch 32
  • TCM3, Planta 4, Puerta 1, Mataró
  • 08302 Barcelona
  • Spain
+34 936
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
LOHAS & Wellness, Life Sciences, Oncology
Corporate Office
  • Avenida Ernest Lluch 32
  • TCM3, Planta 4, Puerta 1, Mataró
  • 08302 Barcelona
  • Spain
+34 936

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Palobiofarma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC 07-May-2024 $7.71M Completed Clinical Trials - Phase 2
8. Grant 16-Jun-2021 Completed Clinical Trials - Phase 2
7. Later Stage VC 09-Jun-2020 Completed Clinical Trials - Phase 2
6. Later Stage VC 26-Sep-2019 Completed Clinical Trials - Phase 2
5. Later Stage VC 17-Jun-2014 Completed Clinical Trials - Phase 2
4. Later Stage VC 20-Jun-2013 Completed Clinical Trials - Phase 2
3. Later Stage VC 01-Mar-2012 Completed Clinical Trials - Phase 2
2. Grant 01-Jan-2011 $2.56M Completed Startup
1. Early Stage VC 17-Sep-2010 $2.56M $2.56M Completed Startup
To view Palobiofarma’s complete valuation and funding history, request access »

Palobiofarma Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
Ordinary
Ordinary
Ordinary 45,538 $1.071092 $23.52 $23.52 1x $23.52 9.53%
Ordinary 72,075 $1.071092 $29.72 $29.72 1x $29.72 15.08%
To view Palobiofarma’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Palobiofarma Patents

  • 145

    Total Documents Applications and Grants

  • Total Patents Families

  • 113

    Granted

  • 4

    Pending

  • Expiring in next 12 mo

Palobiofarma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021327728-A1 (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases Active 21-Aug-2020
AU-2021327728-B2 (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases Active 21-Aug-2020
CA-3190081-A1 (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases Pending 21-Aug-2020
EP-3957308-A1 (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases Inactive 21-Aug-2020
EP-4199922-A1 (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases Active 21-Aug-2020 A61K31/426
To view Palobiofarma’s complete patent history, request access »

Palobiofarma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Palobiofarma Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
European Innovation Council Accelerator/Incubator Minority
INNVIERTE SICC Government Minority
Interreg Government Minority
Agencia de Innovación, Financiación e Internacionalización Empresarial Government Minority
Unirisco Venture Capital Minority
You’re viewing 5 of 13 investors. Get the full list »

Ready to get started?

Request a free trial

Palobiofarma FAQs

  • When was Palobiofarma founded?

    Palobiofarma was founded in 2005.

  • Where is Palobiofarma headquartered?

    Palobiofarma is headquartered in Barcelona, Spain.

  • What is the size of Palobiofarma?

    Palobiofarma has 20 total employees.

  • What industry is Palobiofarma in?

    Palobiofarma’s primary industry is Drug Discovery.

  • Is Palobiofarma a private or public company?

    Palobiofarma is a Private company.

  • What is the current valuation of Palobiofarma?

    The current valuation of Palobiofarma is .

  • What is Palobiofarma’s current revenue?

    The current revenue for Palobiofarma is .

  • How much funding has Palobiofarma raised over time?

    Palobiofarma has raised $21.1M.

  • Who are Palobiofarma’s investors?

    European Innovation Council, INNVIERTE SICC, Interreg, Agencia de Innovación, Financiación e Internacionalización Empresarial, and Unirisco are 5 of 13 investors who have invested in Palobiofarma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process